Back

Puma Biotechnology initiates Phase II ALISCA-Lung2 lung cancer trial

Verifying
  • Puma Biotechnology initiated the ALISCA-Lung2 clinical trial.
  • Alisertib will be evaluated in combination with paclitaxel.
  • The Phase II study targets patients with advanced small cell lung cancer.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.